NRT YHD 001
Alternative Names: NRT-YHD-001; NRT-YHD_001Latest Information Update: 04 Jul 2025
At a glance
- Originator NEORNAT
- Class Antineoplastics; Antisense RNA; MicroRNAs
- Mechanism of Action MicroRNA inhibitors; Thrombospondin 1 expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 03 Jul 2025 Preclinical trials in Liver cancer in South Korea (IV), prior to April 2025
- 25 Apr 2025 NEORNAT anticipates the regulatory approval submissions to the Ministry of Food and drug safety (MFDS) South Korea and the US FDA by the year 2025
- 25 Apr 2025 Pharmacodynamics, pharmacokinetics and adverse events data from the preclinical studies in Liver cancer were presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)